Optimize collaboration and maximize efficiency of drug discovery projects to accelerate innovation

The Sixth Sense of CX with NICE ENLIGHTEN

The emergence of ‘techbio’ organizations and the constant development of new digital technologies in the drug discovery space, like artificial intelligence (AI) and machine learning (ML), are motivating a move to more data-driven drug discovery processes. The need to use new techniques such as predictive modeling and proteomics, or new drug modalities such as antibodies, oncolytic viruses, and proteolysistargeting chimeras (PROTAC), to stay competitive means it is often necessary for companies to partner with several different CROs to take advantage of diverse skillsets and to get the best services at each stage of the drug discovery life cycle. This change in focus has been reflected in recent strategic collaborations, as biopharma competes to partner with companies offering AI-based technologies. Indeed, many smaller, specialized biotech companies are now outsourcing their technologies and know-how alongside their own pipeline of development candidates.

Fill out the form to access content

By submitting my personal data, I acknowledge that Revvity, Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy (available here).

By submitting this form, you agree to have your contact information passed along for the purpose of following up on your interests and in order to receive communications regarding Revvity Signals products, services, and events. The data sent will be processed in Canada and provided to Revvity Signals who will assume responsibility for processing and Opt-out and Information Removal. For more information, please read our Terms of Use, Privacy, Opt-out & Information Removal.